StockNews.com Begins Coverage on Aspira Women’s Health (NASDAQ:AWH)

StockNews.com began coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a report issued on Saturday morning. The firm issued a hold rating on the stock.

Separately, Cantor Fitzgerald reissued a neutral rating and issued a $3.30 price objective on shares of Aspira Women’s Health in a report on Wednesday, April 10th.

Aspira Women’s Health Stock Performance

Shares of NASDAQ:AWH opened at $3.33 on Friday. The company’s fifty day moving average is $3.55 and its two-hundred day moving average is $3.97. Aspira Women’s Health has a 1-year low of $2.31 and a 1-year high of $6.75. The stock has a market capitalization of $41.09 million, a price-to-earnings ratio of -0.28 and a beta of 1.61.

Aspira Women’s Health (NASDAQ:AWH) last announced its quarterly earnings results on Thursday, March 28th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.09. The business had revenue of $2.13 million for the quarter, compared to analysts’ expectations of $2.70 million. Aspira Women’s Health had a negative return on equity of 1,099.32% and a negative net margin of 176.74%. Sell-side analysts expect that Aspira Women’s Health will post -1.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in AWH. B. Riley Wealth Advisors Inc. boosted its position in shares of Aspira Women’s Health by 43.1% in the fourth quarter. B. Riley Wealth Advisors Inc. now owns 179,371 shares of the company’s stock worth $732,000 after buying an additional 53,997 shares during the period. Quantum Private Wealth LLC boosted its position in Aspira Women’s Health by 76.8% during the 4th quarter. Quantum Private Wealth LLC now owns 50,156 shares of the company’s stock worth $205,000 after acquiring an additional 21,788 shares during the period. Northeast Financial Consultants Inc purchased a new position in Aspira Women’s Health during the 3rd quarter valued at about $126,000. Finally, Perkins Capital Management Inc. acquired a new position in shares of Aspira Women’s Health in the 3rd quarter valued at about $268,000. 12.19% of the stock is currently owned by institutional investors and hedge funds.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering.